Oculis Holding AG (OCS) EBT (2022 - 2026)
Oculis Holding AG's (OCS) quarterly EBT came in at -$37.0 million in Q1 2026, little changed year-on-year from -$37.0 million in Q1 2025, and down 24.7% quarter-over-quarter from -$29.6 million in Q4 2025.
Oculis Holding AG (OCS) EBT (2022 - 2026) Analysis & Trends
Oculis Holding AG's EBT history runs 5 years deep, the most recent figure standing at -$37.0 million for Q1 2026.
- On a quarterly basis, EBT changed 0.1% year-over-year to -$37.0 million in Q1 2026; TTM through Mar 2026 was -$21.2 billion, a 9.51% increase from a year earlier, with the FY2025 full-year figure at -$119.6 million, down 22.41% from the prior year.
- EBT retreated to -$37.0 million in Q1 2026 per OCS's latest filing, from -$29.6 million in the prior quarter.
- Across five years, EBT topped out at -$9.5 million in Q4 2022 and bottomed at -$23.3 billion in Q3 2024.
- The 5-year median for EBT is -$26.3 million (2025), against an average of -$2.8 billion.
- Biggest YoY gain for EBT was 62.91% in 2024; the steepest drop was 117219.62% in 2024.
- Year by year, EBT stood at -$9.5 million in 2022, then tumbled by 47.75% to -$14.1 million in 2023, then slumped by 133.82% to -$33.0 million in 2024, then rose by 10.11% to -$29.6 million in 2025, then declined by 24.7% to -$37.0 million in 2026.
- Per Business Quant, the three latest OCS EBT figures stand at -$37.0 million (Q1 2026), -$29.6 million (Q4 2025), and -$21.1 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -36.97 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.31 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 259.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.25 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 831.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 438.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 221.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.97 Mn |
| Dec 31, 2025 | -29.65 Mn |
| Sep 30, 2025 | -21.05 Bn |
| Jun 30, 2025 | -30.68 Mn |
| Mar 31, 2025 | -36.93 Mn |
| Dec 31, 2024 | -32.98 Mn |
| Sep 30, 2024 | -23.28 Bn |
| Jun 30, 2024 | -23.01 Mn |
| Mar 31, 2024 | -18.40 Mn |
| Dec 31, 2023 | -14.11 Mn |
| Sep 30, 2023 | -19.85 Mn |
| Jun 30, 2023 | -14.19 Mn |
| Mar 31, 2023 | -49.62 Mn |
| Dec 31, 2022 | -9.55 Mn |
| Sep 30, 2022 | -10.30 Mn |
| Jun 30, 2022 | -12.77 Mn |